Most-Upgraded StocksMost-Upgraded Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX) $117.28 -2.72 (-2.27%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$117.23▼$120.3250-Day Range$106.07▼$120.0052-Week Range$89.04▼$125.01Volume528,392 shsAverage Volume732,433 shsMarket Capitalization$11.52 billionP/E Ratio63.05Dividend YieldN/APrice Target$131.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.76 Rating ScoreUpside/Downside12.3% Upside$131.71 Price TargetShort InterestHealthy2.32% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.43Based on 24 Articles This WeekInsider TradingSelling Shares$5.31 M Sold Last QuarterProj. Earnings Growth118.69%From $2.14 to $4.68 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.72 out of 5 starsMedical Sector80th out of 942 stocksBiological Products, Except Diagnostic Industry12th out of 161 stocks 3.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $131.71, Neurocrine Biosciences has a forecasted upside of 12.3% from its current price of $117.28.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.32% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 2.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 2.5 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Neurocrine Biosciences this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows12 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,308,163.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions93.54% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 118.69% in the coming year, from $2.14 to $4.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 63.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 63.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 84.18.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 6.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neurocrine Biosciences Stock (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesDecember 9, 2023 | finance.yahoo.comInsider Sell: Chief Medical Officer Eiry Roberts Sells Shares of Neurocrine Biosciences IncDecember 9, 2023 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Rating Reiterated by Canaccord Genuity GroupDecember 9, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 8, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $583,850.00 in StockDecember 7, 2023 | markets.businessinsider.comAnalyst Upholds Hold Rating on Neurocrine Amid Early-Stage Pipeline and Market Strategy ConsiderationsDecember 7, 2023 | benzinga.comNeurocrine Biosciences Stock (NASDAQ:NBIX), Analyst Ratings, Price Targets, PredictionsDecember 7, 2023 | markets.businessinsider.comBalancing Optimism with Caution: Hold Rating on Neurocrine Amidst Ambitious R&D Goals and Uncertain Clinical UpdatesDecember 7, 2023 | markets.businessinsider.comHold Rating on Neurocrine Biosciences Amid Promising Pipeline and Development TimelinesDecember 9, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 7, 2023 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) and ANI Pharmaceuticals (NASDAQ:ANIP) Critical SurveyDecember 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Crinetics Pharmaceuticals (CRNX) and IGM Biosciences (IGMS)December 6, 2023 | markets.businessinsider.comBuy Rating Affirmed for Neurocrine Biosciences Amid Strong R&D and Strategic Growth ProspectsDecember 6, 2023 | markets.businessinsider.comStrong Buy for Neurocrine Biosciences: Strategic R&D Focus and Promising Clinical PipelineDecember 5, 2023 | msn.comNeurocrine gets FDA breakthrough therapy status for crinecerfontDecember 5, 2023 | finance.yahoo.comNeurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal HyperplasiaDecember 4, 2023 | in.investing.comPro Research: Wall Street dives into Neurocrine BiosciencesDecember 3, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Jude Onyia Sells 2,331 SharesDecember 2, 2023 | finance.yahoo.comInsider Sell Alert: Chief Scientific Officer Jude Onyia Sells Shares of Neurocrine Biosciences IncDecember 2, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Darin Lippoldt Sells 10,919 SharesDecember 1, 2023 | finance.yahoo.comNeurocrine Biosciences to Host Analyst Day on December 5, 2023November 30, 2023 | seekingalpha.comNeurocrine Biosciences: Fear Not The IRANovember 30, 2023 | finance.yahoo.comNeurocrine Biosciences Inc's Chief Legal Officer Darin Lippoldt Sells Shares: An Insider AnalysisNovember 14, 2023 | marketwatch.comNeurocrine Biosciences Settles Ingrezza Drug Application SuitNovember 13, 2023 | finance.yahoo.com12 Best Low Beta Stocks To BuyNovember 13, 2023 | markets.businessinsider.comNeurocrine Biosciences Reaches Settlement On INGREZZA ANDA LitigationNovember 13, 2023 | finance.yahoo.comNeurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) LitigationNovember 12, 2023 | morningstar.comNeurocrine Biosciences shares drop as trial failures may 'stunt momentum,' analysts saySee More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$131.71 High Stock Price Target$165.00 Low Stock Price Target$100.00 Potential Upside/Downside+12.3%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$1.86 Trailing P/E Ratio63.05 Forward P/E Ratio54.80 P/E Growth1.25Net Income$154.50 million Net Margins10.71% Pretax Margin14.11% Return on Equity10.54% Return on Assets7.50% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.34 Sales & Book Value Annual Sales$1.49 billion Price / Sales7.74 Cash Flow$1.74 per share Price / Cash Flow67.35 Book Value$17.76 per share Price / Book6.60Miscellaneous Outstanding Shares98,250,000Free Float93,929,000Market Cap$11.52 billion OptionableOptionable Beta0.41 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 65)CEO & Director Comp: $1.9MMr. Matthew C. Abernethy (Age 43)Chief Financial Officer Comp: $1.04MMr. Darin M. Lippoldt Esq. (Age 57)Chief Legal Officer & Corporate Secretary Comp: $921.01kMr. Kyle W. Gano Ph.D. (Age 50)Chief Business Development and Strategy Officer Comp: $921.52kDr. Eiry Wyn Roberts M.D. (Age 59)Chief Medical Officer Comp: $1.04MDr. Jude Onyia Ph.D. (Age 59)Chief Scientific Officer Comp: $621.66kJane SorensenHead of Investor RelationsMs. Julie S. Cooke (Age 57)Chief Human Resources Officer Mr. Eric S. Benevich (Age 58)Chief Commercial Officer Comp: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More ExecutivesKey CompetitorsDr. Reddy's LaboratoriesNYSE:RDYAcceleron PharmaNASDAQ:XLRNElanco Animal HealthNYSE:ELANMomenta PharmaceuticalsNASDAQ:MNTACRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPSold 27,500 shares on 12/7/2023Ownership: 0.051%Darin LippoldtSold 20,830 sharesTotal: $2.50 M ($119.86/share)Wellington Management Group LLPSold 71,500 shares on 12/1/2023Ownership: 1.352%Gary A LyonsSold 5,000 sharesTotal: $583,850.00 ($116.77/share)Jude OnyiaSold 2,331 sharesTotal: $264,731.67 ($113.57/share)View All Insider TransactionsView All Institutional Transactions NBIX Stock Analysis - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price target for 2024? 21 Wall Street research analysts have issued twelve-month target prices for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $165.00. On average, they anticipate the company's stock price to reach $131.71 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2023? Neurocrine Biosciences' stock was trading at $119.44 on January 1st, 2023. Since then, NBIX shares have decreased by 1.8% and is now trading at $117.28. View the best growth stocks for 2023 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024. View our NBIX earnings forecast. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Tuesday, October, 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.91 by $0.09. The company earned $498.80 million during the quarter, compared to analyst estimates of $479.09 million. Neurocrine Biosciences had a net margin of 10.71% and a trailing twelve-month return on equity of 10.54%. Neurocrine Biosciences's revenue for the quarter was up 28.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.69 earnings per share. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and SPDR S&P Biotech ETF (XBI). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.58%), Wellington Management Group LLP (1.35%), DSM Capital Partners LLC (1.25%), Armistice Capital LLC (1.24%), Brown Advisory Inc. (1.12%) and Braidwell LP (0.99%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NBIX) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.